MK-1084, Merck’s investigational KRAS G12C inhibitor, showed a manageable safety profile along with antitumor activity in the ...

In this video interview, Ron Lanton, partner, Lanton Law, discusses how a potential increase in drug costs could affect the ...

In patients with first-line metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors, ...

In a post-hoc analysis from the Phase III ARANOTE trial, new results show metastatic castration-sensitive prostate cancer ...

Randomization monitoring is a type of statistical/central monitoring, which ICH notes should be performed by appropriately qualified/trained individuals, (e.g., biostatisticians). 4 Thus, ...

In this video interview, Michel van Harten, MD, CEO, myTomorrows, highlights the potential of artificial intelligence in digital twin technology.

For the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer, patritumab deruxtecan did not meet statistical significance for overall survival in the HERTHENA-Lung02 ...

Pimicotinib, an investigational colony stimulating factor-1 receptor inhibitor being developed by Abbisko Therapeutics and licensed by Merck KGaA, met MANEUVER’s primary endpoint of objective response ...